Skip to content

Adults with Cystic Fibrosis (CF) & Exercise Intolerance

Search Clinical Trials

Trial Objectives

This exercise study is investigating how an already FDA approved drug for treatment of pulmonary vascular disease, sildenafil (Revatio ®), impacts exercise tolerance and capacity in people with cystic fibrosis (CF). Understanding and developing exercise tolerance is important for people with CF. Participants will be randomized to either the study drug group or the placebo group and complete exercise testing. 

Who Can Participate

Individuals with moderate to severe CF lung disease.

Age: 18+ Gender: Any

Estimated Time Commitment

16 weeks, five in-person visits, three phone contacts

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Grant Warren

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Jewish Health and Dr. Taylor-Cousar, with Cystic Fibrosis Foundation via Augusta University

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required